UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): January 5, 2024

Immunocore Holdings plc
(Exact name of registrant as specified in its Charter)

England and Wales
001-39992
Not Applicable
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)

92 Park Drive, Milton Park
Abingdon, Oxfordshire,
United Kingdom

OX14 4RY
(Address of principal executive offices)
 
(Zip Code)
+44 1235 438600
(Registrant’s telephone number, including area code)
 
Not Applicable
(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
 
Trading
Symbol(s)
 
Name of each exchange on which registered
American Depositary Shares, each representing one ordinary share, nominal value £0.002 per share
 
IMCR
 
The Nasdaq Stock Market LLC
Ordinary share, nominal value £0.002 per share*
 
*
 
The Nasdaq Stock Market LLC
 
* Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC.
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 


Item 2.02.
Results of Operations and Financial Condition.
 
On January 5, 2024, Immunocore Holdings plc (the “Company”) announced a preliminary estimate of the amount of its cash and cash equivalents at December 31, 2023. The Company preliminarily estimates that its cash and cash equivalents as of December 31, 2023 were approximately $450 million.
 
The information in this Item 2.02 is preliminary, has not been audited and is subject to change pending completion of the Company’s audited financial statements for the year ended December 31, 2023. It is possible that the Company or its independent registered public accounting firm may identify items that require the Company to make adjustments to the amounts included in this Item 2.02, and such changes could be material. Additional information and disclosures would also be required for a more complete understanding of the Company’s financial position and results of operations as of December 31, 2023.
 
Item 7.01.
Regulation FD Disclosure.
 
On January 5, 2024, the Company issued a press release announcing its strategic priorities and planned pipeline expansion for 2024. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
 
Also on January 5, 2024, the Company updated its corporate presentation to reflect certain business and strategic updates. The Company intends to use this presentation in meetings with analysts, investors and others from time to time, including its presentation by management at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024 at 9:00 a.m. PT. A copy of the presentation is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference herein. The corporate presentation and a webcast of the Company’s presentation at the 42nd Annual J.P. Morgan Healthcare Conference will also be available in the “Investors/Media” section of the Company’s website at www.immunocore.com. The Company’s website and any information contained on the Company’s website are not incorporated by reference into this Current Report on Form 8-K.
 
The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.
 
Item 8.01
Other Events.
 
On January 5, 2024, the Company published an updated pipeline chart of KIMMRAK and its therapeutic candidates in development, which is filed as Exhibit 99.3 to this Current Report on Form 8-K and incorporated by reference herein.
 
Item 9.01. 
Financial Statements and Exhibits
 
 
Exhibit No.
Description
 
Press Release dated January 5, 2024.
 
January 2024 Corporate Presentation.
 
Pipeline Chart.


SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
IMMUNOCORE HOLDINGS PLC
 

Dated: January 5, 2024
By:
/s/ Bahija Jallal, Ph.D.
 
   
Name:
Bahija Jallal, Ph.D.
   
Title:
Chief Executive Officer




Exhibit 99.1


Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation

Increasing commercial access to KIMMTRAK (tebentafusp-tebn) globally, and pursuing future growth opportunities with two registrational trials in advanced cutaneous melanoma and adjuvant uveal melanoma

Multiple clinical readouts expected to start in 2Q 2024 for IMC-F106C (PRAME HLA-A02) from Phase 1/2 clinical trial monotherapy and combination arms; IMC-P115C (PRAME HLA-A02 HLE) and IMC-T119C (PRAME HLA-A24) ImmTAC candidates on track for expected CTA/IND submission in 2024

Submitted clinical trial applications (CTA) for IMC-R117C, a first-in-class ImmTAC targeting PIWIL1 for colorectal and other gastrointestinal cancers

Data from IMC-M113V Phase 1 clinical trial in people living with HIV expected in the second half of 2024

Advancing novel TCR bispecific candidates for autoimmune diseases

Company to present at 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 9:00 AM P.T. / 5:00 PM GMT

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 05 January, 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today sets out its strategic priorities for 2024 and announced the addition of two new pre-clinical candidates for autoimmune diseases to its pipeline.

“We continue the global commercial roll out of KIMMTRAK, now launched in 10 countries, and are pursuing future growth opportunities for KIMMTRAK with two registrational trials in advanced cutaneous melanoma and in adjuvant uveal melanoma,” said Bahija Jallal, Chief Executive Officer of Immunocore. “We are advancing our PRAME ImmTAC including our first Phase 3 clinical trial in melanoma and expect to present clinical data from our Phase 1/2 clinical trial in melanoma, ovarian, and lung cancer throughout 2024. Today we add two new autoimmune candidates to our pipeline, expanding the potential of our platform to a third therapeutic area.”

Key Strategic Priorities 2024
Our strategic priorities are to bring transformative medicines to patients with cancer, infectious diseases, and autoimmune diseases. In 2024, our priorities will be:


Growing sales of KIMMTRAK (tebentafusp-tebn) in the United States and globally in patients with HLA-A*02:01-positive metastatic uveal melanoma, and expanding KIMMTRAK beyond its initial approved indication with the registrational trials for advanced (second-line or later) cutaneous melanoma (TEBE-AM) and adjuvant uveal (or ocular) melanoma (ATOM).

Advancing our PRAME franchise in multiple solid tumors and broadening the addressable population. Randomization is expected to begin in the first quarter of 2024 in the registrational trial for IMC-F106C in first-line advanced cutaneous melanoma (PRISM-MEL-301), and we expect to present data from the Phase 1/2 clinical trial monotherapy and combination cohorts throughout 2024. We further expect to submit investigational new drug (IND) applications or clinical trial applications (CTA) for IMC-P115C (PRAME HLA-A2 Half-Life-Extended) and IMC-T119C (PRAME HLA-A24) candidates in 2024.

Immunocore Holdings plc, 92 Park Drive, Milton Park, Abingdon, Oxon, OX14 4RY, UK
T: +44 (0)1235 438600  |  www.immunocore.com
Registered in England no: 6456207  |  VAT No. GB 939 6694 55


Bringing novel ImmTAC candidates to the clinic, leading with IMC-R117C, a first-in-class ImmTAC candidate targeting PIWIL1 with focus on colorectal and gastrointestinal cancers.

Evaluating the potential for a functional cure in infectious diseases with lead candidates for human immunodeficiency virus (HIV) and hepatitis B virus (HBV).

Initiating CMC manufacturing for the Company’s first two autoimmune candidates – including the first in class, tissue-specific, TCR bispecific PD1 agonist for type 1 diabetes and a novel non-HLA restricted (universal) PD1 agonist for dermatological diseases.

KIMMTRAK expansion strategy
In 2024, the Company plans to expand access to KIMMTRAK to more patients in the United States, Europe and globally, as it continues to establish the therapy as standard of care for the first line treatment for metastatic uveal melanoma in countries where it is launched. As of 2023 year-end, KIMMTRAK has been launched in ten countries and is approved in 38 countries.

The Company also continues to enroll patients into a Phase 2/3 clinical trial (TEBE-AM) to investigate the potential of KIMMTRAK in advanced cutaneous melanoma, with randomization expected to be completed in the Phase 2 portion during the third quarter of 2024. Topline data from the Phase 2 portion of the trial is expected to be available by the fourth quarter of 2024.

In addition, in 2023, the Company signed an agreement for a European Organisation for Research and Treatment of Cancer (EORTC)-sponsored trial to study KIMMTRAK as adjuvant therapy for uveal (or ocular) melanoma (ATOM). The Company anticipates that the EORTC will randomize the first patient in the second half of 2024.

PRAME franchise

PRISM-MEL301 – First PRAME Phase 3 clinical trial with IMC-F106C in first-line advanced cutaneous melanoma

In August 2023, the Company announced plans to start a registrational Phase 3 trial with IMC-F106C in cutaneous melanoma. The trial will randomize patients with HLA-A*02:01-positive, first-line advanced cutaneous melanoma to IMC-F106C + nivolumab versus a control arm of either nivolumab or nivolumab + relatlimab, depending on the country where the patient is enrolled. The Company plans to randomize the first patient in this trial in the first quarter of 2024.

Phase 1/2 clinical trial of IMC-F106C targeting PRAME-A02 in multiple solid tumors

In addition to progressing IMC-F106C into a registrational trial in cutaneous melanoma, the Company is continuing to enroll patients in the monotherapy and combination arms of the Phase 1/2 clinical trial across multiple tumor types, including expansion arms for patients with advanced ovarian, non-small cell lung carcinoma, endometrial, and melanoma. In August 2023, the Company provided an updated analysis of the original 18 melanoma patients (initially presented at ESMO in September 2022), which continued to show promising durability of the clinical activity (range of duration of partial response from 6 months to 17 months). The Company expects to report clinical data from the ongoing monotherapy and combination cohorts throughout 2024 including cutaneous melanoma (expected in Q2 2024), ovarian (expected by Q3 2024), and non-small cell lung carcinoma (expected by Q4 2024).

Page 2 of 8

IMC-P115C (PRAME-A02 Half-Life Extended) & IMC-T119C (PRAME-A24)

The Company is expanding the PRAME franchise with two new PRAME ImmTAC candidates, IMC-P115C (PRAME-A02 HLE) and IMC-T119C (PRAME-A24) for solid tumors, which are both on track for investigational new drug (IND) or clinical trial application (CTA) submissions for IMC-P115C in the second quarter of 2024 and the second half of 2024 for IMC-T119C.

IMC-R117C (PIWIL1) for colorectal and other gastrointestinal cancers

The Company has leveraged its proprietary peptidomic (ImmSPECT) database to validate a novel target, PIWIL1. PIWIL1 is believed to play a role in tumor progression and is expressed across a range of tumors, including colorectal which is historically insensitive to immune checkpoints, as well as gastrointestinal and pancreatic cancers. PIWIL1 is also reported to be a negative prognostic marker and the Company believes IMC-R117C is the first PIWIL1-targeted immunotherapy. The Company submitted a CTA to regulatory authorities in December 2023, and expects the trial to start this year.

Enrolling ImmTAV candidates for a functional cure in infectious diseases

The Company continues to enroll people living with HIV in the multiple ascending dose (MAD) part of a Phase 1 clinical trial with IMC-M113V, to identify a safe and tolerable dosing schedule. This study will also test whether IMC-M113V could lead to reduction in the viral reservoir and, after stopping all therapies (antiretroviral therapies and IMC-M113V), delay or prevent HIV rebound (known as functional cure). The MAD part of the trial will enroll up to 28 participants. The Company expects to present a data update from the Phase 1 clinical trial in the second half of 2024.

In 2023, the Company amended the design of the ongoing Phase 1 trial with IMC-I109V for people living with HBV to include HBV-positive hepatocellular carcinoma. The Company continues to enroll patients into the trial in 2024.

Tissue-specific down modulation of the immune system for autoimmune diseases
The Company is expanding its platform into autoimmune with two first in class new bispecific candidates entering the Company’s pipeline. The key differentiator of the ImmTAAI platform is tissue-specific down modulation of the immune system. When tethered to the tissue of interest, the new candidates supress pathogenic T cells via PD1 receptor agonism.

The first candidate, IMC-S118AI (PPIxPD1), is targeted specifically to the pancreatic beta-cell and is intended for disease-modifying treatment in type 1 diabetes. IMC-S118AI recognizes a peptide from pre-proinsulin presented by HLA-A*02:01 on beta-cells.

Page 3 of 8

The second target is present in the skin and intended to treat inflammatory dermatological diseases.  The candidate is an antigen presenting cell (APC) tethered ImmTAAI and is not HLA restricted (e.g. universal for all populations).

Preliminary Year-End 2023 cash position
Preliminary unaudited cash and cash equivalents is approximately $443 million USD as of December 31, 2023.

42nd Annual J.P. Morgan Healthcare Conference

The Company has updated its corporate presentation to reflect these business and strategic updates. Additionally, the Immunocore management team will discuss these updates during a live and webcast presentation at the 42nd Annual J.P. Morgan Healthcare Conference, on Wednesday January 10, 2024, at 9:00 a.m. Pacific Standard Time (PST). The presentation and webcast will be available in the ‘Investors/Media’ section of Immunocore’s website at www.immunocore.com. A replay of the presentation will be made available for a limited time.

##

About ImmTAC® molecules for cancer
Immunocore’s proprietary T cell receptor (TCR) technology generates a novel class of bispecific biologics called ImmTAC (Immune mobilizing monoclonal TCRs Against Cancer) molecules that are designed to redirect the immune system to recognize and kill cancerous cells. ImmTAC molecules are soluble TCRs engineered to recognize intracellular cancer antigens with ultra-high affinity and selectively kill these cancer cells via an anti-CD3 immune-activating effector function. Based on the demonstrated mechanism of T cell infiltration into human tumors, the ImmTAC mechanism of action holds the potential to treat hematologic and solid tumors, regardless of mutational burden or immune infiltration, including immune “cold” low mutation rate tumors.

About ImmTAV molecules and infectious diseases
ImmTAV (Immune mobilising monoclonal TCRs Against Virus) molecules are novel bispecifics that, like ImmTAC (Immune mobilising monoclonal TCRs Against Cancer) molecules, are designed to enable the immune system to recognize and eliminate virally infected cells.

Immunocore is advancing clinical candidates to cure patients with HIV and hepatitis B virus (HBV). The Company aims to achieve sustained control of HIV after patients stop anti-retroviral therapy (ART), without the risk of virological relapse or onward transmission. This is known as ‘functional cure’. For the treatment of HBV, the Company aims to achieve sustained loss of circulating viral antigens and markers of viral replication after stopping medication for people living with chronic HBV.

About ImmTAAI molecules and autoimmune diseases
ImmTAAI (Immune mobilising monoclonal TCRs Against Autoimmune) molecules are novel bispecifics that are designed for tissue-specific down modulation of the immune system. When tethered to the tissue of interest, ImmTAAI candidates supress pathogenic T cells via PD1 receptor agonism. The Company is currently advancing two candidates for autoimmune conditions, including Type 1 Diabetes and inflammatory dermatological diseases.

Page 4 of 8

About PRISM-MEL301 – Phase 3 trial with IMC-F106C (PRAMExCD3) in 1L advanced cutaneous melanoma
The Phase 3 registrational trial will randomize patients with previously untreated, HLA-A*02:01-positive, advanced melanoma to IMC-F106C + nivolumab versus nivolumab or nivolumab + relatlimab, depending on the country where the patient is enrolled. The study will initially randomize to three arms: two IMC-F106C dose regimens (40 mcg and 160 mcg) and control arm and will discontinue one of the IMC-F106C dose regimens after an initial review of the first 60 patients randomized to the two experimental arms (90 patients randomized total). The primary endpoint of the trial is progression free survival (PFS) by blinded independent central review (BICR), with secondary endpoints of overall survival (OS) and overall response rate (ORR).

About the IMC-F106C-101 Phase 1/2 Trial
IMC-F106C-101 is a first-in-human, Phase 1/2 dose escalation trial in patients with multiple solid tumor cancers including non-small cell lung cancer (NSCLC), small-cell lung cancer (SCLC), endometrial, ovarian, cutaneous melanoma, and breast cancers. The Phase 1 dose escalation trial was designed to determine the maximum tolerated dose (MTD), as well as to evaluate the safety, preliminary anti-tumor activity and pharmacokinetics of IMC-F106C, a bispecific protein built on Immunocore’s ImmTAC technology, and the Company’s first molecule to target the PRAME antigen. The Company has initiated patient enrollment into four expansion arms in cutaneous melanoma, ovarian, NSCLC, and endometrial carcinomas. The IMC-F106C-101 trial is adaptive and includes the option for Phase 2 expansion, allowing for approximately 100 patients treated per tumor type in the Phase 1 and 2 expansion arms. Dose escalation continues in additional solid tumors as well as plans for combination arms with standards-of-care, including checkpoint inhibitors, chemotherapy, and tebentafusp.

About TEBE-AM - Phase 2/3 trial with tebentafusp (gp100xCD3) in second-line or later cutaneous melanoma
The trial is randomizing patients with second-line or later cutaneous melanoma who have progressed on an anti-PD1, received prior ipilimumab and, if applicable, received a BRAF kinase inhibitor. Patients will be randomized to one of three arms including tebentafusp, as monotherapy or in combination with an anti-PD1, and a control arm. The Phase 2 portion of the trial will include 40 patients per arm.

About the ATOM Phase 3 trial
The EORTC-led Phase 3 clinical trial will include sites in 10 EU countries and the United States and will randomize patients with HLA-A*02:01-positive high-risk primary uveal melanoma after definitive treatment, by surgery or radiotherapy, and no evidence of metastatic disease on imaging. The trial is expected to enroll a total of 290 patients who will be randomized 1:1 to one of two arms: KIMMTRAK as monotherapy or observation. The primary endpoint of the trial is relapse-free survival (RFS), with secondary objectives of overall survival and safety and tolerability of tebentafusp. Exploratory objectives include the comparison of the health-related quality of life between the treatment arms and the evaluation of the role of circulating tumor DNA as a biomarker for the presence of residual disease.

About Uveal Melanoma
Uveal melanoma is a rare and aggressive form of melanoma, which affects the eye. Although it is the most common primary intraocular malignancy in adults, the diagnosis is rare, and up to 50% of people with uveal melanoma will eventually develop metastatic disease. Unresectable or metastatic uveal melanoma typically has a poor prognosis and had no approved treatment until KIMMTRAK.

Page 5 of 8

About KIMMTRAK®
KIMMTRAK is a novel bispecific protein comprised of a soluble T cell receptor fused to an anti-CD3 immune-effector function. KIMMTRAK specifically targets gp100, a lineage antigen expressed in melanocytes and melanoma. This is the first molecule developed using Immunocore’s ImmTAC technology platform designed to redirect and activate T cells to recognise and kill tumour cells. KIMMTRAK has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.

IMPORTANT SAFETY INFORMATION

Cytokine Release Syndrome (CRS), which may be serious or life-threatening, occurred in patients receiving KIMMTRAK. Monitor for at least 16 hours following first three infusions and then as clinically indicated. Manifestations of CRS may include fever, hypotension, hypoxia, chills, nausea, vomiting, rash, elevated transaminases, fatigue, and headache. CRS occurred in 89% of patients who received KIMMTRAK with 0.8% being grade 3 or 4. Ensure immediate access to medications and resuscitative equipment to manage CRS. Ensure patients are euvolemic prior to initiating the infusions. Closely monitor patients for signs or symptoms of CRS following infusions of KIMMTRAK. Monitor fluid status, vital signs, and oxygenation level and provide appropriate therapy. Withhold or discontinue KIMMTRAK depending on persistence and severity of CRS.

Skin Reactions

Skin reactions, including rash, pruritus, and cutaneous edema occurred in 91% of patients treated with KIMMTRAK. Monitor patients for skin reactions. If skin reactions occur, treat with antihistamine and topical or systemic steroids based on persistence and severity of symptoms. Withhold or permanently discontinue KIMMTRAK depending on the severity of skin reactions.

Elevated Liver Enzymes

Elevations in liver enzymes occurred in 65% of patients treated with KIMMTRAK. Monitor alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total blood bilirubin prior to the start of and during treatment with KIMMTRAK. Withhold KIMMTRAK according to severity.

Embryo-Fetal Toxicity
KIMMTRAK may cause fetal harm. Advise pregnant patients of potential risk to the fetus and patients of reproductive potential to use effective contraception during treatment with KIMMTRAK and 1 week after the last dose.

The most common adverse reactions (≥30%) in patients who received KIMMTRAK were cytokine release syndrome, rash, pyrexia, pruritus, fatigue, nausea, chills, abdominal pain, edema, hypotension, dry skin, headache, and vomiting. The most common (≥50%) laboratory abnormalities were decreased lymphocyte count, increased creatinine, increased glucose, increased AST, increased ALT, decreased hemoglobin, and decreased phosphate.

Page 6 of 8

For more information, please see full Summary of Product Characteristics (SmPC) or full U.S. Prescribing Information (including BOXED WARNING for CRS).

About KIMMTRAKConnect
Immunocore is committed to helping patients who need KIMMTRAK obtain access via our KIMMTRAKConnect program. The program provides services with dedicated nurse case managers who provide personalized support, including educational resources, financial assistance, and site of care coordination. To learn more, visit KIMMTRAKConnect.com or call 844-775-2273.

About Immunocore
Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune, and infectious disease. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. The Company’s most advanced oncology TCR therapeutic, KIMMTRAK has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.

Page 7 of 8

Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “may”, “will”, “believe”, “expect”, “plan”, “anticipate” and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These statements include, but are not limited to, statements regarding the commercial performance of KIMMTRAK, including expanded access to KIMMTRAK to more patients in the United States, Europe and globally; the potential benefits and advantages KIMMTRAK will provide for patients; expectations regarding the design, progress, timing, enrollment, scope, expansion, and results of the Company’s existing and planned clinical trials, those of the Company’s collaboration partners or the combined clinical trials with the Company’s collaboration partners; the timing and sufficiency of clinical trial outcomes to support potential approval of any of the Company’s product candidates or those of, or combined with, its collaboration partners; the Company’s goals to develop and commercialize product candidates based on its KIMMTRAK platform alone or with collaboration partners; the expected submission of investigational new drug applications or clinical trial applications; the potential regulatory approval, expected clinical benefits and availability of the Company’s product candidates; the Company’s preliminary unaudited cash and cash equivalents; sales, marketing, manufacturing and distribution requirements; and potential growth opportunities and trends, including in connection with future product launches. Any forward-looking statements are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual events or results to differ materially and adversely from those set forth in or implied by such forward-looking statements, many of which are beyond the Company’s control. These risks and uncertainties include, but are not limited to, the impact of worsening macroeconomic conditions on the Company’s business, financial position, strategy and anticipated milestones, including Immunocore’s ability to conduct ongoing and planned clinical trials; Immunocore’s ability to obtain a clinical supply of current or future product candidates or commercial supply of KIMMTRAK or any future approved products, including as a result of health epidemics or pandemics, war in Ukraine, the conflict between Hamas and Israel, or global geopolitical tension; Immunocore’s ability to obtain and maintain regulatory approval of its product candidates, including KIMMTRAK; Immunocore’s ability and plans in continuing to establish and expand a commercial infrastructure and to successfully launch, market and sell KIMMTRAK and any future approved products; Immunocore’s ability to successfully expand the approved indications for KIMMTRAK or obtain marketing approval for KIMMTRAK in additional geographies in the future; the delay of any current or planned clinical trials, whether due to patient enrollment delays or otherwise; Immunocore’s ability to successfully demonstrate the safety and efficacy of its product candidates and gain approval of its product candidates on a timely basis, if at all; competition with respect to market opportunities; unexpected safety or efficacy data observed during preclinical studies or clinical trials; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials or future regulatory approval; Immunocore’s need for and ability to obtain additional funding, on favorable terms or at all, including as a result of worsening macroeconomic conditions, including changes inflation and interest rates and unfavorable general market conditions, and the impacts thereon of the war in Ukraine, the conflict between Hamas and Israel, and global geopolitical tension; Immunocore’s ability to obtain, maintain and enforce intellectual property protection for KIMMTRAK or any of its product candidates it or its collaborators are developing; and the success of Immunocore’s current and future collaborations, partnerships or licensing arrangements. These and other risks and uncertainties are described in greater detail in the section titled "Risk Factors" in Immunocore’s filings with the Securities and Exchange Commission, including Immunocore’s most recent Annual Report on Form 20-F for the year ended December 31, 2022 filed with the Securities and Exchange Commission on March 1, 2023, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information, except as required by law. In addition, as the reported cash and cash equivalents in this press release are preliminary, have not been audited and are subject to change pending completion of the Company’s audited financial statements for the year ended December 31, 2023, it is possible that the Company or its independent registered public accounting firm may identify items that require the Company to make adjustments to the amount included in this release, and such changes could be material. Additional information and disclosures would also be required for a more complete understanding of the Company’s financial position and results of operations as of December 31, 2023.

CONTACT:
Immunocore
Sébastien Desprez, Head of Communications
T: +44 (0) 7458030732
E: mailto:sebastien.desprez@immunocore.com          
Follow on Twitter: @Immunocore

Investor Relations
Clayton Robertson, Head of Investor Relations
T: +1 215-384-4781
E: ir@immunocore.com


Page 8 of 8


Exhibit 99.2


 Transformative immunomodulating medicines for patients  January 2024 


 This presentation contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “may”, “will”, “believe”, “expect”, “plan”, “anticipate” and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. All statements, other than statements of historical facts, included in this presentation are forward-looking statements. These statements include, but are not limited to, Immunocore’s capabilities across oncology, autoimmune and infectious disease therapeutic areas and its ability to grow and further development the PRAME franchise; the estimated market size and patient population for KIMMTRAK and Immunocore’s other product candidates; the three growth areas of KIMMTRAK including HLA-A02+ melanoma, metastatic cutaneous melanoma and adjuvant uveal melanoma; expected submission of investigational new drug applications or clinical trial applications; the potential regulatory approval, expected clinical benefits and availability of Immunocore’s product candidates; the commercial performance of KIMMTRAK including planned launches in additional countries, expanded access to KIMMTRAK in the United States and globally, and indication expansion; the ability to enter into pricing agreements and to translate such pricing agreement into a successful launch; the potential benefits and advantages KIMMTRAK and Immunocore’s other product candidates will provide for patients; the benefits of Immunocore’s collaboration with the European Organisation for Research and Treatment of Cancer (EORTC); expectations regarding the design, progress, timing, enrollment, scope, expansion, and results of Immunocore’s existing and planned clinical trials, those of Immunocore’s collaboration partners or the combined clinical trials with Immunocore’s collaboration partners; the timing and sufficiency of clinical trial outcomes to support potential approval of any of Immunocore’s product candidates or those of, or combined with, its collaboration partners; Immunocore’s goals to develop and commercialize product candidates based on its KIMMTRAK platform alone or with collaboration partners; Immunocore’s ability to develop new product candidates using its discovery engine; Immunocore’s ability to initiate CMC manufacturing for autoimmune candidates on the expected timeline, or at all; potential growth opportunities and trends, including in connection with product launches; and Immunocore’s preliminary unaudited cash and cash equivalents. Any forward-looking statements are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual events or results to differ materially and adversely from those set forth in or implied by such forward-looking statements, many of which are beyond Immunocore’s control. These risks and uncertainties include, but are not limited to, the impact of worsening macroeconomic conditions on Immunocore’s business, financial position, strategy and anticipated milestones, including Immunocore’s ability to conduct ongoing and planned clinical trials; Immunocore’s ability to obtain a clinical supply of curr ent or future product candidates or commercial supply of KIMMTRAK or any future approved products, including as a result of health epidemics or pandemic, war in Ukraine, the conflict between Hamas and Israel, or global geopolitical tension; Immunocore’s ability to obtain and maintain regulatory approval of its product candidates, including KIMMTRAK; Immunocore’s ability and plans in continuing to establish and expand a commercial infrastructure and to successfully launch, market and sell KIMMTRAK and any future approved products; Immunocore’s ability to successfully expand the approved indications for KIMMTRAK or obtain marketing approval for KIMMTRAK in additional geographies in the future; the delay of any current or planned clinical trials, whether due to patient enrollment delays or otherwise; Immunocore’s ability to successfully demonstrate the safety and efficacy of its product candidates and gain approval of its product candidates on a timely basis, if at all; competition with respect to market opportunities; unexpected safety or efficacy data observed during preclinical studies or clinical trials; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials or future regulatory approval; Immunocore’s need for and ability to obtain additional funding, on favorable terms or at all, including as a result of worsening macroeconomic conditions, including changes inflation and interest rates and unfavorable general market conditions, and the impacts thereon of the war in Ukraine, the conflict between Hamas and Israel, and global geopolitical tension; Immunocore’s ability to obtain, maintain and enforce intellectual property protection for KIMMTRAK or any product candidates it is developing; and the success of Immunocore’s current and future collaborations, partnerships or licensing arrangements. These and other risks and uncertainties are described in greater detail in the section titled "Risk Factors" in Immunocore’s filings with the Securities and Exchange Commission, including Immunocore’s most recent Annual Report on Form 20-F for the year ended December 31, 2022 filed with the Securities and Exchange Commission on March 1, 2023, as well as discussions of potential risks, uncertainties, and other important factors in Immunocore’s subsequent filings with the Securities and Exchange Commission.  All forward looking statements contained in this presentation speak only as of the date on which they were made and should not be relied upon as representing its views as of any subsequent date. Except to the extent required by law, Immunocore undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.  Certain information contained in this presentation relates to or is based on studies, publications, surveys, and other data obtained from third party sources and Immunocore’s own internal estimates and research. While Immunocore believes these third party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy, or completeness of, any information obtained from third party sources.  KIMMTRAK™ is a trademark owned or licensed to Immunocore.  2  Forward Looking Statements 
 

 3  Harnessing the immune system to fight disease with targeted, off-the-shelf, bispecific, soluble T cell receptors (TCRs)  TCR therapeutics can target >90% of the human proteome  Targeting  >90%  Proteome  ImmTAX 
 

 4  Platform candidates and capabilities across 3 therapeutic areas  Oncology  Activation  of the immune system     Downmodulation   of the immune system  Infectious diseases  Autoimmune diseases  ImmTACs  ImmTAVs  ImmTAAIs 
 

 5  1 Platinum refractory or resistant serous ovarian carcinoma.; 2. Program is wholly owned, development costs being provided by the Bill & Melinda Gates Foundation (BMGF), Immunocore retains all development and commercialization rights in the developed world.; 3. Program is not HLA restricted (ie. universal for all populations)  Leading bispecific TCR pipeline  Oncology  Infectious  Autoimmune  Candidate  Target (HLA type)  gp100 (A02)  Indication  Uveal (ocular) melanoma  IND-enabling  Phase 1  Phase 2  Phase 3  Approved  Catalyst  Adjuvant uveal (ocular) melanoma  ATOM sponsore  d by  Phase 3 Start | 2H24  2L+ cutaneous melanoma  TEBE-AM  Phase 2 Data | 4Q24  IMC-F106C  PRAME (A02)  1L cutaneous melanoma PRISM-MEL-301  Phase 3 Start | 1Q24  2L+ cutaneous melanoma  Phase 1 Clinical Data  2Q24 – 4Q2024  PRR ovarian1  2L+ NSCLC  Advanced endometrial  Multiple solid tumors Mono. & combina  tion arms  IMC-P115C  PRAME-HLE (A02)  Multiple solid tumors  IND/CTA | Mid-24  IMC-T119C  PRAME (A24)  Multiple solid tumors  IND/CTA | 4Q24  IMC-R117C  PIWIL1 (A02)  Colorectal, gastric, pancreatic  Phase 1 Start | 2024  IMC-M113V2  Gag (A02)  Human Immunodeficiency Virus (HIV)  MAD Data | 2H24  IMC-I109V  Envelope (A02)  Hepatitis B Virus (HBV)  IMC-S118AI  PPI (A02)  Type 1 Diabetes  Undisclosed  (universal)3  Dermatology  New candidate added to pipeline January 2024. 
 

 Maximizing potential of KIMMTRAK®  in HLA-A02+  melanoma  6 
 

 7  † Estimated number of HLA-A*02:01 positive patients per year in the US and EU.  KIMMTRAK’s  3 growth areas  Continued US &  global growth in metastatic uveal melanoma  Phase 2/3 trial in 2L+ metastatic cutaneous melanoma (TEBE-AM)  Phase 3 trial in adjuvant uveal melanoma (ATOM)  Today  Adjuvant Uveal Melanoma  ~1,200 pts†  2L+ Metastatic  Cutaneous Melanoma  ~2,000 - 4,000 pts†  Metastatic  Uveal Melanoma  ~1,000 pts†  KIMMTRAK Estimated Market Opportunity (HLA-A02+) 
 

 8  KIMMTRAK® (tebentafusp-tebn)  Delivering a survival benefit to HLA-02+ metastatic uveal melanoma patients  Approved in  38  countries  Launched and reimbursed in  10  countries  ~$168M  Q1-Q3 sales 
 

 9  Nathan, P. et al. New England Journal of Medicine 2021; 385:1196-1206. Hassel, J., Piperno-Neumann, S. et al. New England Journal of Medicine 2023; 10.1056/NEJMoa2304753.  Overall survival benefit of KIMMTRAK vs investigator’s choice in 1L mUM  3-year OS follow-up  27%  KIMMTRAK arm  17%  Investigator’s choice arm2 
 

 10  KIMMTRAK TRAEs mostly in first month and decrease thereafter  Adverse events manageable, very low rate of discontinuation (2%) & no treatment-related deaths  * Rash, hypotension, and liver function tests are composite terms for a list of related adverse events of any grade AE: adverse event; TRAE: treatment-related adverse event  The KIMMTRAK U.S. Prescribing Information has a BOXED WARNING for the risk of Cytokine Release Syndrome. CRS, which may be serious or life-threatening, occurred in patients receiving KIMMTRAK. Monitor for at least 16 hours following first three infusions and then as clinically indicated. 
 

 Rationale for KIMMTRAK in adjuvant uveal melanoma  Clinical activity expected to be highest in adjuvant setting with minimal disease burden  1. Piperno-Neumann, et. al. AACR Annual Meeting 2021; 2. Sullivan R, et. Al. Cancer Res (2023) 83 (7_Supplement): 1035.; 3. Carvajal, R.D., et. al. Nat Med 28, 2364–2373 (2022);  11  0.36 OS HR for small tumor (M1a, < 3 cm largest lesion)1 ctDNA reduction in 1st line > 2nd+ line mUM  1st line  (N=123)  37% ctDNA  clearance2  2nd + line  (N=94)  13% ctDNA  clearance3  Largest metastatic lesion  OS Hazard ratio  M1a (<3.0 cm)  0.36  M1b (3.1-8.0 cm)  0.71  M1c (≥8.1 cm)  0.76 
 

 Treatment phase  Follow-up  1:1 Randomization  12  ATOM – Phase 3 KIMMTRAK adjuvant UM trial design  Global trial led by European Organisation for Research and Treatment of Cancer (EORTC)  EORTC – European Organisation for Research and Treatment of Cancer.  Investigator discretion on subsequent therapy for metastatic disease  Anticipate EORTC to start randomization in 2H 2024  KIMMTRAK (tebentafusp) (Q1W IV)  R  ~300 HLA-A*02:01 patients  Within 3 months of definitive treatment of high risk primary uveal (or ocular) melanoma  No evidence of metastatic disease on imaging  Key endpoints  Primary: Relapse-Free Survival (RFS)  Secondary: Overall survival  Exploratory: ctDNA response  Observation 
 

 13  Hamid O, et al. JITC (2023). Middleton et al., ASCO 2022. Remote = Patients received prior anti-PD1 but it was not most recent therapy prior to enrolment. Immediately prior = anti-PD1 was most recent therapy prior to enrolment.  KIMMTRAK active in cutaneous melanoma (CM)  Time from prior anti-PD(L)1  1-yr OS  2-yr OS  Remote  75%  22%  Immediately prior  75%  23%  Benchmark  55%  N/A  Monthly  Dosing frequency  Weekly  Remained weekly  Durable disease control  60 cutaneous melanoma (all progressed on prior anti-PD1) received KIMMTRAK (tebentafusp) + durvalumab*  Time since last dose of prior  anti-PD1 does not impact outcome  Durable  response  Phase 1/2 study of KIMMTRAK + checkpoints in CM patients who progressed on prior anti-PD1 
 

 Treatment phase  OS follow-up  1:1:1 Randomization  14  TEBE-AM – Phase 2/3 trial for previously treated, advanced melanoma patients  Randomization to ‘real world’ treatment as a control arm  Investigator discretion on subsequent therapy: local standard, supportive care or other clinical trials.  Collect data on subsequent therapy, survival and ctDNA sample.  Phase  Primary Endpoint  Per Arm Size  2  ctDNA and OS  40  3  OS  170  Optionality to review Phase 2 data to inform changes to Phase 3, including  dropping an Arm and optimize powering of study  KIMMTRAK  (tebentafusp)  KIMMTRAK + anti-PD-1  Straight to follow-up  R  HLA-A*02:01 advanced melanoma  Uveal melanoma excluded  Prior anti-PD(L)1  Progression within 6 months last dose  Prior ipilimumab  Prior targeted therapy (BRAFm)  Anticipate Phase 2 topline data by 4Q 2024 
 

 PRAME Franchise: A02, A24, A02-HLE  15 
 

 PRAME is negative prognostic marker in multiple cancers  PRAME broadly expressed in multiple tumors including:  IMC-F106C demonstrated durable clinical activity in Phase 1 (ESMO 2022)  Registrational 1L melanoma trial expected to begin in 1Q 2024  Multiple clinical readouts from Phase 1/2 expected throughout 2024  16  1 PRAME prevalence derived from immunohistochemistry and RTqPCR of patient samples and analysis of TCGA. 2 Epidemiology data from cancer registries and Decision Resources, Annual incidence of metastatic patients.  PRAME prevalent in multiple solid tumors  ~150,000  PRAME+, HLA-A02 + patients per year  +30%  Additional patient opportunity  with PRAME HLA-A24  Cutaneous Melanoma  NSCLC  Ovarian  Endometrial 
 

 IMC-F106C (n = 55)  Preferred Term (MedDRA v23.1)  0.3 – 10 mcg†  (n = 18)  20 – 320 mcg†  (n = 37)  Total  (n = 55)  All grades (events in ≥ 25% of patients), n (%)  At least one event  18 (100)  34 (92)  52 (95)  Pyrexia*  10 (56)  21 (57)  31 (56)  Cytokine release syndrome  5 (28)  22 (59)  27 (49)  Fatigue  6 (33)  13 (35)  19 (35)  Hypotension*  3 (17)  15 (41)  18 (33)  Chills  9 (50)  8 (22)  17 (31)  Nausea  7 (39)  10 (27)  17 (31)  Rash  3 (17)  12 (32)  15 (27)  Grade ≥ 3 (Events in > 1 patient), n (%)  At least one event  6 (33)  13 (35)  19 (35)  Lymphopenia  1 (6)  7 (19)  8 (15)  Aspartate aminotransferase increased  3 (17)  1 (3)  4 (7)  Anemia  1 (6)  2 (5)  3 (5)  Alanine aminotransferase increased  2 (11)  0  2 (4)  Arthralgia  1 (6)  1 (3)  2 (4)  Pyrexia*  0  2 (5)  2 (4)  IMC-F106C was well tolerated  Most frequent related AE was Grade 1/2 CRS, consistent with proposed mechanism  * Includes events reported as a sign/symptom of CRS. † Safety presented by intended target escalation dose on Day 15. 1/37 patients received only a single dose of 2 mcg and did not reach target dose of ≥ 20 mcg. Hamid, O., et al., Annals of Oncology (ESMO 2022) 33 (suppl_7): S331-S355.  17  MTD not reached  No treatment-related discontinuation or  Grade 5 related AEs  CRS events were all manageable  Majority (77%) within first 3 doses  71% Grade 1  29% Grade 2  No Grade ≥ 3 CRS  Adverse events attenuate over time 
 

 18  Majority of patients have durable tumor response or stabilization  IMC-F106C (ESMO 2022)  NSCLC, non small cell lung carcinoma. Hamid, O., et al., Annals of Oncology (ESMO 2022) 33 (suppl_7): S331-S355. 
 

 19  IMC-F106C monotherapy melanoma activity shows durability  Update to ESMO 2022 melanoma patients (n=18)  Data cut-off May 2023 from live data base. DoR= duration of response. ^ Patient had disease progression after Month 12.  Durable response  Durable disease control  Radiation to index lesion after this date  DoR = 10 mo^  DoR = 6 mo  DoR = 17 mo  DoR = 16+ mo  DoR = 12 mo  Melanoma type  PRAME status  Prior therapy  Cutaneous (n=7)  5+, 1 unknown;  1 negative  All prior anti-PD1 & ipilimumab  Uveal (n=5)  All +  Prior tebentafusp  Uveal (n=6)  All +  Tebentafusp naïve  PRAME negative 
 

 20  * HLA-A*02:01; 1.Company estimates IMC-T119C targeting PRAME-HLA-A24 expands addressable population of PRAME-A02 by ~30% in non-overlapping patients  Executing across core areas for PRAME franchise  Data to be presented from 2Q 2024 and thereafter  Randomization expected 1Q 2024  Monotherapy  Standard-of-care combinations  Checkpoint inhibitor  combinations  Chemotherapy combinations  Endometrial  Monotherapy expansion  NSCLC  Monotherapy expansion  Ovarian  Monotherapy expansion  Cutaneous melanoma  Monotherapy expansion  40 mcg dose optimization  (Project Optimus)  ImmTAC combination  Registrational Studies  New  PRISM-MEL301  First line melanoma, approximately  10,000 HLA-A2+ patients per year  Building Franchise  PRAME-A02 +  Half Life Extended (HLE)  PRAME-A24 (HLA-A24)  Population Expansion by ~30%1  IND/CTA in 2024 
 

 21  PRISM-MEL301: First-line advanced cutaneous melanoma Phase 3  Design based on Type B FDA meeting  a Use of nivolumab or nivolumab + relatlimab as control will be country specific. b Represents target dose after intra-patient escalation. c ITT: intent to treat.  Randomization Treatment phase Follow-up  R  Key inclusion criteria  Previously untreated, advanced melanoma  HLA-A*02:01  No prospective PRAME testing  Stratification factors  AJCC M stage  Prior anti-PD1 adjuvant therapy  BRAF V600 status  Key endpoints  Primary: PFS by BICR  Secondary: OS, ORR  Exploratory: ctDNA  IMC-F106C + nivolumab (q4w)  Nivolumab (q4w) or Nivolumab + relatlimab (q4w)a  N~325  N~325  q1w 12 wks  q2w To 1 year  q4w To 2 years  Control arm  40 mcg IMC-F106Cb + nivolumab  160 mcg IMC-F106Cb + nivolumab  Interim analysis of two experimental arms No pause in randomization during review Drop one experimental arm  All patients in the ‘go-forward’ arm included in ITTC analysis  Randomization expected to start Q1 2024  Initial randomization includes comparison of two IMC-F106C regimens  (~90 patients or 30/arm) 
 

 Prevalence of PRAME  expression1  Tumor type  HLA-A*02:01+, PRAME+  metastatic patients (G7)2  70-100%  Endometrial  >10K  Melanoma  >10K  Ovarian  >15K  NSCLC-squamous  >30K  50-70%  NSCLC-adeno  >40K  SCLC  >15K  TNBC  >5K  SCCHN  Gastric  20-50%  RCC  >30K  Esophageal  Cholangiocarcinoma  Cervical  22  1 PRAME prevalence derived from immunohistochemistry and RTqPCR of patient samples and analysis of TCGA. 2 Epidemiology data from cancer registries and Decision Resources, Annual incidence of metastatic patients.  PRAME-A02 has the potential to benefit a large number of patients  Total  ~150,000  PRAME+, HLA-A02 patients/year 
 

 Novel ImmTAC candidate for GI cancers from our discovery engine  23 
 

 Negative prognostic marker in multiple cancers, role in tumor progression  Expressed in CRC, historically insensitive to IO, and across major subgroups*  25% CRC have broad PIWIL1 expression (with > 75% of tumor cells positive)  24  PIWIL1, piwi-like protein1, CRC, colorectal cancer. * Estimated across colorectal, esophageal, gastric, pancreatic, ovarian, endometroid cancers  IMC-R117C: A first-in-class therapy targeting PIWIL1 in colorectal  PIWIL1 RNA in situ hybridization  Normal colon Colon adenocarcinoma  PIWIL1 detected  ~20K colorectal + ~15K other tumors  patients positive for PIWIL1 and HLA-A02  CTA submitted in December 2023 
 

 Pursuing a functional cure in infectious diseases 
 

 Aiming for functional cure in HIV by reducing/eliminating the reservoir  Anti-retroviral therapy (ART) suppresses reservoir but cannot eliminate  26  Rare (i.e. 1 in a million) HIV-infected T cells (reservoir) persist despite ART1,2  Historically, rapid viral rebound occurs after ART interruption at median ~2 weeks3  Peak viremia  ART interruption  Flow cytometry of CD4+ T cells from peripheral blood  Fun, Axel et al. Scientific reports vol. 7 43231. 2017  Pardons M et al. PLoS Pathog 15(2), 2019, e1007619  3 Feher C et al. Open Forum Infect Dis, 2019; 6: ofz485; N = 249 (from non interventional studies), detectable viral load (VL) defined as > 50 copies/mL, time to detectable VL - IQR = 2-4 weeks. 
 

 27  Active dose definition: ≥ 4-fold increase in plasma IL-6 at 8-24 hours post-dose.  Single dose of IMC-M113V well tolerated and biologically active  Phase 1 Soluble T cell Receptors In Viral Eradication (‘STRIVE’) HIV trial  Key inclusion criteria  Participants living with HIV (PLWH) on anti-retroviral therapy (ART)  Regimen:  Single dose  Key endpoint:  Primary: Safety  Key biomarker:  T cell activation  15 mcg was well tolerated and met pre-defined biomarker threshold  for expansion  Single Ascending Dose IL-6 increase (marker of T cell engagement)  0  1  10  100  Cohort 2  (5 mcg)  Serum IL6 concentration (pg/ml)  Baseline  8h  24h  Day 8  0  1  10  100  Cohort 1  (1.6 mcg)  Serum IL6 concentration (pg/ml)  Baseline  8h  24h  Day 8  0  1  10  100  Cohort 3  (15 mcg; n = 10)  Serum IL6 concentration (pg/ml)  Baseline  8h  24h  Day 8  0.1  1  10  100  Serum IL-6 fold change from baseline  4 fold change  0  0.1  1  10  100  Serum IL-6 fold change from baseline  Baseline  8h  24h  Day 8  4 fold change  0  0.1  1  10  100  Serum IL-6 fold change from baseline  Baseline  8h  24h  Day 8  4 fold change  15 mcg, n = 10  1.6 mcg, n = 1  5 mcg, n = 1 
 

 28  HIV STRIVE multiple ascending dose portion now enrolling  Goal is to determine safety and anti-viral activity of IMC-M113V  PLWH: People living with HIV; ART: Anti-retroviral therapy; ATI: ART treatment interruption.  Key inclusion criteria  PLWH on ART  Regimen:  Weekly for 12 weeks  Step dose (initially 15 mcg)  Target dose (> 30 mcg)  Viral rebound (magnitude and kinetics)  IMC-M113V  Week  ART  ART interruption  ART  ART interrupted  Weekly monitoring  Reservoir quantification (blood):  1 2 3 4 5 6 7 8 9 10 11 12  36  Endpoint  Interpretation  Cell-associated HIV Gag RNA  Active viral transcription  Endpoint  Interpretation  Plasma HIV RNA  Infectious virus 
 

 29  IMC-I109V: Encouraging signs of activity observed in HBV  Initial results from single 0.8 mcg dose presented at EASL 2022  1 Bourgeois, et al. EASL 2022. Arrow indicates timing of administration of IMC-I109V.  Patient #1  Patient #2  Patient #3  Induction of IL-6 in all 3 patients1  Transient decrease in HBsAg coincided with transient increase in ALT1  PRE 4h  8h  24h 48h Day Day  8 29  0  2  4  6  Serum IL-6 concentrations  8  Time  Serum IL-6 (pg/ml)  Patient 1  Patient 2  Patient 3  1  8  22  29  15  Days  1  8  22  29  15  Days  1000  1200  2200  2000  1400  HBsAg (IU/ml)  1  8  22  29  15  Days  10  20  30  40  ALT (U/L) 
 

 Pioneering tissue- specific immune suppression for treatment of autoimmune diseases  30 
 

 31  Platform suppress T-cells only when ImmTAAI is tethered to target tissue  ImmTAAI: tissue-specific down modulation of the immune system  Vision for autoimmunity and inflammation landscape  Current Systemic immune suppression, even if  inflammation in single tissue  Future  Down modulation of immune system localized to inflamed tissue  Tissue-tethered targeting of  HLA- antigen  PD1 agonist suppresses T cells  Fc fusion  infrequent dosing  ImmTAAI  ImmTAAI Mechanism  Reduces T cell activation  Non-competitive with natural PDL1  Promotes T cell exhaustion  Does not interfere with Treg  Suppresses NK activation 
 

 Inhibits T cell activity only when tissue-tethered  Clustering at immune synapse drives potency  Suppress IL2 release (T cell activation marker)  T cells remain suppressed after ImmTAAI removed  32  ImmTAAI: tissue-specific and lasting immune suppression  T cells activated with target cells +/- ImmTAAI for 8 days then washed and re-stimulated on Day 10 with target cells in absence of ImmTAAI (yellow or red)  0  20  40  60  80  100  Potential to treat autoimmune disease and modify disease course  120  Non-tethered  Tethered  ImmTAAI (nM)  T cell activity (%)  T cell  Target cell  250  0  500  1000  750  IL-2 pg/mL  T cell re-stimulation (after ImmTAAI removed)  ✱  Reduced IL-2 upon  re-stimulation  No Yes  ImmTAAI in initial stimulation  T cells washed  Initial T cell stimulation  -  ImmTAAI  -  -  T cell  re-stimulation 
 

 33  Pancreas-tethered ImmTAAI (HLA-A02) protects against killing by autoreactive T cells  *quantity measured as area under the curve;1.Current Diabetes Reports (2023) 23:277–291 (~700K in US & ~700K in EU5)  IMC-S118AI (PPIxPD1) for type 1 diabetes  HLA-A02 restricted, ~50% of type 1 diabetes patients  60  80  100  120  140  160  � cell number*  ImmTAAI binds specifically to pre-pro- insulin (PPI) peptide on pancreatic β-cells  Potent protection of β-cells from killing by autoreactive T cells  �-cell marker  Immune system attacks and kills the beta cells responsible for  controlling glucose levels through the release of insulin  ~1.4M  HLA-A2+ type 1 diabetes patients (US + EU5)1 
 

 ImmTAAI binds specifically to APC in skin  34  Antigen presenting cell (APC) tethered ImmTAAI inhibits T cell activation and promotes long-lasting immune suppression  Universal (non-HLA restricted) candidate for dermatology  Potent inhibition of cytokine release in  primary cell assays  Non-tethered ImmTAAI (30 nM) has no effect  Tethered ImmTAAI  ImmTAAI (nM)  IL-2 release  (%stim control)  Potential dermatological diseases: atopic dermatitis, psoriasis, and lichenoid skin diseases 
 

 Upcoming milestones  35 
 

 36  Looking ahead  Preliminary and unaudited cash position of ~$443 million as of December 31, 2023  Commercial milestones  Clinical milestones  KIMMTRAK  Continued global growth including commercial launches in Australia and Canada 2024  KIMMTRAK  Expansion  Topline data from Ph 2 2L+ cutaneous melanoma (TEBE-AM) 4Q 2024  First patient randomized in Ph 3 registrational adjuvant uveal melanoma trial (ATOM); led by EORTC 2H 2024  PRAME Franchise  First patient randomized in Ph 3 registrational 1L cutaneous melanoma (PRISM-MEL301) 1Q 2024  Cutaneous melanoma data from Phase 1 PRAME trial 2Q 2024  Serous ovarian data from Phase 1 PRAME trial 3Q 2024  NSCLC data from Phase 1 PRAME trial 4Q 2024  IND/CTA for PRAME-HLE trial Mid-2024  IND/CTA for PRAME-A24 trial 4Q 2024  PIWIL1  First patient dosed in PIWIL1 Phase 1 trial 2024  Infectious Diseases  Data from Ph 1 HIV MAD/POC trial 2H 2024  Enroll Ph 1 HBV MAD (now including HCC) trial 2024  Autoimmune  Diseases  Initiating CMC manufacturing for autoimmune candidates 2024 
 

 Thank you 







Exhibit 99.3
 5  1 Platinum refractory or resistant serous ovarian carcinoma.; 2. Program is wholly owned, development costs being provided by the Bill & Melinda Gates Foundation (BMGF), Immunocore retains all development and commercialization rights in the developed world.; 3. Program is not HLA restricted (ie. universal for all populations)  Leading bispecific TCR pipeline  Oncology  Infectious  Autoimmune  Candidate  Target (HLA type)  gp100 (A02)  Indication  Uveal (ocular) melanoma  IND-enabling  Phase 1  Phase 2  Phase 3  Approved  Catalyst  Adjuvant uveal (ocular) melanoma  ATOM sponsore  d by  Phase 3 Start | 2H24  2L+ cutaneous melanoma  TEBE-AM  Phase 2 Data | 4Q24  IMC-F106C  PRAME (A02)  1L cutaneous melanoma PRISM-MEL-301  Phase 3 Start | 1Q24  2L+ cutaneous melanoma  Phase 1 Clinical Data  2Q24 – 4Q2024  PRR ovarian1  2L+ NSCLC  Advanced endometrial  Multiple solid tumors Mono. & combina  tion arms  IMC-P115C  PRAME-HLE (A02)  Multiple solid tumors  IND/CTA | Mid-24  IMC-T119C  PRAME (A24)  Multiple solid tumors  IND/CTA | 4Q24  IMC-R117C  PIWIL1 (A02)  Colorectal, gastric, pancreatic  Phase 1 Start | 2024  IMC-M113V2  Gag (A02)  Human Immunodeficiency Virus (HIV)  MAD Data | 2H24  IMC-I109V  Envelope (A02)  Hepatitis B Virus (HBV)  IMC-S118AI  PPI (A02)  Type 1 Diabetes  Undisclosed  (universal)3  Dermatology  New candidate added to pipeline January 2024.